Prostate Cancer: ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration
Sensitive Prostate Cancer (ARASENS)
Is Darolutamide (ODM-201) effective at keeping your cancer under control when given
in addition to standard treatment which includes androgen deprivation therapy (ADT)
and docetaxel chemotherapy?
Basic Study Information
Purpose:Location: Cancer Center
You will be randomly assigned to a treatment group, Darolutamide (ODM-201) or placebo.
You will have a 1:1 chance of receiving Darolutamide (ODM-201) and a 1:1 chance of
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02799602?term=17777&rank=1
Study Reference #: IGUP16141
Lead Researcher (Principal Investigator)
Lead Researcher: Elizabeth Guancial
Study Contact InformationStudy Coordinator: Ayesha Khan
Phone: (585) 275-3351
Additional Study Details
Learn More About These Conditions
More information about Prostate Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search